Exchange: OTC·Updated 03:59 PM EDT

VRNOVerano Holdings Corp.

$5.77
$0.13
(2.31%)
Today
EarningsAug 5
Mkt Cap$416.9M
Vol85,914.00
News
all
press releases
Cannabis Operator Cresco Down 28.5% YTD: How to Play the Stock?
CRLBF is down 28.5% YTD as revenue pressure and competition persist, but retail expansion and improving estimates could shape its next move.
Zacks
News Placeholder
More News
News Placeholder
Verano Advances U.S. Exchange Uplisting Plans: Time to Invest?
VRNO's reverse split and prior U.S. redomestication support potential exchange uplisting plans as the company expands stores and product offerings.
Zacks
News Placeholder
Does Epidiolex Make Jazz Pharmaceuticals a Unique Cannabis Stock?
JAZZ gains unique cannabis exposure through Epidiolex as strong sales growth and patent protection boost long-term visibility.
Zacks
News Placeholder
Verano Holdings Corp. (VRNO) Reports Q1 Loss, Tops Revenue Estimates
Verano Holdings Corp. (VRNO) delivered earnings and revenue surprises of +15.79% and +3.82%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
US Cannabis Major Reports $208M Q1 Revenue and Initiates $20M Buyback
Cannabis stocks have been in motion since April 23, when the Trump administration moved to reclassify cannabis from Schedule I to Schedule III under the DEA's controlled substances framework. As reported by CNBC, the shift does not legalize marijuana federally, but it removes longstanding research barriers, opens banking access that was previously blocked, and critically, exempts cannabis companies from IRS Code Section 280E. This exemption allows operators to deduct standard business expenses like rent and payroll for the first time, a change with direct, material implications for ...
AllPennyStocks.com
News Placeholder
US Cannabis Major Reports $208M Q1 Revenue and Initiates $20M Buyback
Cannabis stocks have been in motion since April 23, when the Trump administration moved to reclassify cannabis from Schedule I to Schedule III under the DEA's controlled substances framework. As reported by CNBC, the shift does not legalize marijuana federally, but it removes longstanding research barriers, opens banking access that was previously blocked, and critically, exempts cannabis companies from IRS Code Section 280E. This exemption allows operators to deduct standard business expenses like rent and payroll for the first time, a change with direct, material implications for ...
AllPennyStocks.com
News Placeholder
Schedule III for Some, Not All: Understanding the DOJ's Cannabis Shift
DOJ narrows cannabis reform, shifting select marijuana products to Schedule III while leaving broader federal restrictions intact.
Zacks
News Placeholder
Verano Holdings Corp. (VRNO) Reports Q4 Loss, Tops Revenue Estimates
Verano Holdings Corp. (VRNO) delivered earnings and revenue surprises of -66.67% and +0.36%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates
MacroGenics (MGNX) delivered earnings and revenue surprises of +47.31% and +71.24%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Cannabis Stock VRNO Rises 40% in a Year: Time to Buy, Sell or Hold?
Verano stock has surged more than 40% in a year amid U.S. marijuana rescheduling optimism, but revenue headwinds and rising competition may keep investors cautious.
Zacks
<
1
2
...
>

Advertisement|Remove ads.